CYTARABINE ACCORD cytarabine 5000 mg/50 mL injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

cytarabine accord cytarabine 5000 mg/50 ml injection vial

accord healthcare pty ltd - cytarabine, quantity: 5000 mg - injection, solution - excipient ingredients: trometamol; water for injections; macrogol 400 - cytarabine is indicated primarily for:,? induction and maintenance of remission in acute myelocytic leukaemia of both adults and children.,it has also been found to be useful in the treatment of other leukaemias such as:,? acute lymphocytic leukaemia,? chronic myelocytic leukaemia (blast phase).,cytarabine may be used alone or in combination with other antineoplastic agents, the best results are often obtained with combination therapy.,children with non-hodgkin?s lymphoma have benefited from a combination drug program (lsa2l2) that includes cytarabine.,remissions induced by cytarabine not followed by maintenance treatment have been brief. maintenance therapy has extended these and provided useful and comfortable remissions with relatively little toxicity.,cytarabine has been used intrathecally in meningeal leukaemia. focal leukaemic involvement of the central nervous system may not respond to intrathecal cytarabine and may better be treated with radiotherapy.

CYTARABINE ACCORD cytarabine 1000 mg/10 mL injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

cytarabine accord cytarabine 1000 mg/10 ml injection vial

accord healthcare pty ltd - cytarabine, quantity: 1000 mg - injection, solution - excipient ingredients: water for injections; macrogol 400; trometamol - cytarabine is indicated primarily for:,? induction and maintenance of remission in acute myelocytic leukaemia of both adults and children.,it has also been found to be useful in the treatment of other leukaemias such as:,? acute lymphocytic leukaemia,? chronic myelocytic leukaemia (blast phase).,cytarabine may be used alone or in combination with other antineoplastic agents, the best results are often obtained with combination therapy.,children with non-hodgkin?s lymphoma have benefited from a combination drug program (lsa2l2) that includes cytarabine.,remissions induced by cytarabine not followed by maintenance treatment have been brief. maintenance therapy has extended these and provided useful and comfortable remissions with relatively little toxicity.,cytarabine has been used intrathecally in meningeal leukaemia. focal leukaemic involvement of the central nervous system may not respond to intrathecal cytarabine and may better be treated with radiotherapy.

CYTARABINE ACC cytarabine 40 mg/2 mL injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

cytarabine acc cytarabine 40 mg/2 ml injection vial

accord healthcare pty ltd - cytarabine, quantity: 40 mg - injection, solution - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections; sodium chloride - cytarabine is indicated primarily for:,? induction and maintenance of remission in acute myelocytic leukaemia of both adults and children.,it has also been found to be useful in the treatment of other leukaemias such as:,? acute lymphocytic leukaemia,? chronic myelocytic leukaemia (blast phase).,cytarabine may be used alone or in combination with other antineoplastic agents, the best results are often obtained with combination therapy.,children with non-hodgkin?s lymphoma have benefited from a combination drug program (lsa2l2) that includes cytarabine.,remissions induced by cytarabine not followed by maintenance treatment have been brief. maintenance therapy has extended these and provided useful and comfortable remissions with relatively little toxicity.,cytarabine has been used intrathecally in meningeal leukaemia. focal leukaemic involvement of the central nervous system may not respond to intrathecal cytarabine and may better be treated with radiotherapy.

CYTARABINE ACCORD cytarabine 500 mg/5 mL injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

cytarabine accord cytarabine 500 mg/5 ml injection vial

accord healthcare pty ltd - cytarabine, quantity: 500 mg - injection, solution - excipient ingredients: water for injections; macrogol 400; trometamol - cytarabine is indicated primarily for:,? induction and maintenance of remission in acute myelocytic leukaemia of both adults and children.,it has also been found to be useful in the treatment of other leukaemias such as:,? acute lymphocytic leukaemia,? chronic myelocytic leukaemia (blast phase).,cytarabine may be used alone or in combination with other antineoplastic agents, the best results are often obtained with combination therapy.,children with non-hodgkin?s lymphoma have benefited from a combination drug program (lsa2l2) that includes cytarabine.,remissions induced by cytarabine not followed by maintenance treatment have been brief. maintenance therapy has extended these and provided useful and comfortable remissions with relatively little toxicity.,cytarabine has been used intrathecally in meningeal leukaemia. focal leukaemic involvement of the central nervous system may not respond to intrathecal cytarabine and may better be treated with radiotherapy.

CYTARABINE ACCORD cytarabine 100 mg/1 mL injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

cytarabine accord cytarabine 100 mg/1 ml injection vial

accord healthcare pty ltd - cytarabine, quantity: 100 mg - injection, solution - excipient ingredients: water for injections; macrogol 400; trometamol - cytarabine is indicated primarily for:,? induction and maintenance of remission in acute myelocytic leukaemia of both adults and children.,it has also been found to be useful in the treatment of other leukaemias such as:,? acute lymphocytic leukaemia,? chronic myelocytic leukaemia (blast phase).,cytarabine may be used alone or in combination with other antineoplastic agents, the best results are often obtained with combination therapy.,children with non-hodgkin?s lymphoma have benefited from a combination drug program (lsa2l2) that includes cytarabine.,remissions induced by cytarabine not followed by maintenance treatment have been brief. maintenance therapy has extended these and provided useful and comfortable remissions with relatively little toxicity.,cytarabine has been used intrathecally in meningeal leukaemia. focal leukaemic involvement of the central nervous system may not respond to intrathecal cytarabine and may better be treated with radiotherapy.

CYTARABINE ACCORD cytarabine 2000 mg/20 mL injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

cytarabine accord cytarabine 2000 mg/20 ml injection vial

accord healthcare pty ltd - cytarabine, quantity: 2000 mg - injection, solution - excipient ingredients: water for injections; macrogol 400; trometamol - cytarabine is indicated primarily for:,? induction and maintenance of remission in acute myelocytic leukaemia of both adults and children.,it has also been found to be useful in the treatment of other leukaemias such as:,? acute lymphocytic leukaemia,? chronic myelocytic leukaemia (blast phase).,cytarabine may be used alone or in combination with other antineoplastic agents, the best results are often obtained with combination therapy.,children with non-hodgkin?s lymphoma have benefited from a combination drug program (lsa2l2) that includes cytarabine.,remissions induced by cytarabine not followed by maintenance treatment have been brief. maintenance therapy has extended these and provided useful and comfortable remissions with relatively little toxicity.,cytarabine has been used intrathecally in meningeal leukaemia. focal leukaemic involvement of the central nervous system may not respond to intrathecal cytarabine and may better be treated with radiotherapy.

CYTARABINE ACC cytarabine 100 mg/5 mL injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

cytarabine acc cytarabine 100 mg/5 ml injection vial

accord healthcare pty ltd - cytarabine, quantity: 100 mg - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; water for injections; sodium hydroxide - cytarabine is indicated primarily for:,? induction and maintenance of remission in acute myelocytic leukaemia of both adults and children.,it has also been found to be useful in the treatment of other leukaemias such as:,? acute lymphocytic leukaemia,? chronic myelocytic leukaemia (blast phase).,cytarabine may be used alone or in combination with other antineoplastic agents, the best results are often obtained with combination therapy.,children with non-hodgkin?s lymphoma have benefited from a combination drug program (lsa2l2) that includes cytarabine.,remissions induced by cytarabine not followed by maintenance treatment have been brief. maintenance therapy has extended these and provided useful and comfortable remissions with relatively little toxicity.,cytarabine has been used intrathecally in meningeal leukaemia. focal leukaemic involvement of the central nervous system may not respond to intrathecal cytarabine and may better be treated with radiotherapy.

CYTARABINE ACCORD cytarabine 4000 mg/40 mL injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

cytarabine accord cytarabine 4000 mg/40 ml injection vial

accord healthcare pty ltd - cytarabine, quantity: 4000 mg - injection, solution - excipient ingredients: water for injections; macrogol 400; trometamol - cytarabine is indicated primarily for:,? induction and maintenance of remission in acute myelocytic leukaemia of both adults and children.,it has also been found to be useful in the treatment of other leukaemias such as:,? acute lymphocytic leukaemia,? chronic myelocytic leukaemia (blast phase).,cytarabine may be used alone or in combination with other antineoplastic agents, the best results are often obtained with combination therapy.,children with non-hodgkin?s lymphoma have benefited from a combination drug program (lsa2l2) that includes cytarabine.,remissions induced by cytarabine not followed by maintenance treatment have been brief. maintenance therapy has extended these and provided useful and comfortable remissions with relatively little toxicity.,cytarabine has been used intrathecally in meningeal leukaemia. focal leukaemic involvement of the central nervous system may not respond to intrathecal cytarabine and may better be treated with radiotherapy.

CYTARABINE injection United States - English - NLM (National Library of Medicine)

cytarabine injection

mylan institutional llc - cytarabine (unii: 04079a1rdz) (cytarabine - unii:04079a1rdz) - cytarabine 100 mg in 5 ml - cytarabine injection in combination with other approved anti-cancer drugs is indicated for remission induction in acute non-lymphocytic leukemia of adults and pediatric patients. it has also been found useful in the treatment of acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. intrathecal administration of cytarabine injection (preservative free preparation only) is indicated in the prophylaxis and treatment of meningeal leukemia. cytarabine injection is contraindicated in those patients who are hypersensitive to the drug.

CYTARABINE injection, solution United States - English - NLM (National Library of Medicine)

cytarabine injection, solution

hospira, inc. - cytarabine (unii: 04079a1rdz) (cytarabine - unii:04079a1rdz) - cytarabine 20 mg in 1 ml - cytarabine in combination with other approved anticancer drugs is indicated for remission induction in acute non-lymphocytic leukemia of adults and children. it has also been found useful in the treatment of acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. intrathecal administration of cytarabine is indicated in the prophylaxis and treatment of meningeal leukemia. cytarabine injection is contraindicated in those patients who are hypersensitive to the drug.